Novel Approaches to Assessing Cannabis Impaired Driving (NAACID)

Eligibility Criteria

• * The following are inclusion criteria for participants to be enrolled in any of the four phases of the study:
• 1. Participants who are ≥21 years old and ≤55 years old
• 2. Participants who are able to provide written, informed consent
• 3. Participants with active healthcare coverage (including health insurance, Medicaid, etc.)
• 4. Participants who are willing to complete up to two in-person study visits (one for Phases 1 \& 2, and two for Phases 3 \& 4), including up to two urine drug screens, two alcohol breathalyzer tests, and one urine pregnancy test (if applicable)
• 5. Participants who agree to refrain from using non-prescription psychotropic drugs (e.g., ecstasy), hallucinogens, and synthetic cannabinoids during the study
• 6. Participants who agree to refrain from drinking \>3 alcoholic drinks the day prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4)
• 7. Participants who agree to refrain from using any cannabis products for at least 8 hours prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4)
• 8. Participants who are willing to provide and use their own cannabis product that has been procured from a licensed dispensary, is labeled with THC potency, and contains \<2% CBD (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4)
• 9. Participants who agree to have a sober driver pick them up after the data collection study visit (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4)
• 10. Participants who take at least 2 inhalations ("hits") during their typical inhalational (smoking/vaporizing) sessions, or ingest at least 5 mg of THC when they consume edible cannabis products (cannabis use groups only)
• 11. Participants who are willing to provide a sample of their cannabis to be independently tested for potency and terpene content (Phases 1, 3 \& 4 only)
• * The following are exclusion criteria for participants to be enrolled in any of the four phases of the study:
• 1. Prisoners
• 2. Participants who have nocturnal schedules (e.g., work night shifts)
• 3. Participants with a history of abuse or addiction to substances other than cannabis (e.g., prescription and non-prescription pharmaceuticals, alcohol, or illicit drugs)
• 4. Participants who have expressed an interest in substance abuse treatment within the 60 days prior to study enrollment
• 5. Participants who report consuming an average of \>3 alcoholic drinks per day in the 30 days prior to study enrollment
• 6. Participants with any past or current diagnosis of schizophrenia, narcolepsy, heart disease, epilepsy, or a traumatic brain injury
• 7. Participants who are currently experiencing untreated bipolar disorder, major depression, sleep apnea, or other uncontrolled medical conditions as determined by the investigators (e.g., hypertension)
• 8. Participants with a known balance or gait disorder
• 9. Participants with color blindness (Phase 2 only)
• 10. Participants who currently wear hard contact lenses for vision correction (Phase 2 only)
• 11. Participants who have donated 450 mL or more of blood in the two weeks prior to study enrollment
• 12. Participants who are pregnant or breastfeeding (female participants only)
• 13. Participants who report never using cannabis before in their lifetime (Phases 1 \& 2 only)
• 14. Participants with a history of clinically significant adverse event(s) associated with cannabis intoxication (e.g., lightheadedness, nausea, dizziness, etc., cannabis use groups only)
• 15. Participants with uncorrected visual acuity disorder, defined as binocular vision worse than 20/40 (Phases 2, 3 \& 4 only; determined at screening)
• 16. Participants with a body mass index \>40 kg/m2 (determined at screening)
• 17. Participants with a positive breath alcohol test (breathalyzer) at screening
• 18. Participants who are otherwise unsuitable for inclusion in the study, based on the opinion of the investigator